We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Tenaya Therapeutics (TNYA) USD0.0001

Sell:$6.16 Buy:$6.17 Change: $0.18 (2.84%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
Change: $0.18 (2.84%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
Change: $0.18 (2.84%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Tenaya Therapeutics, Inc. is a preclinical stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing a pipeline of disease-modifying therapies developed using its product platforms and capabilities to target defined sub-populations of patients with rare or other prevalent forms of heart disease. The Company is advancing product candidates from three diverse product platforms, such as gene therapy, cellular regeneration, and precision medicine. It is also advancing a diverse pipeline that includes both gene therapies and small molecules. The Company’s capabilities include disease models, capsid engineering, promoters and regulatory elements, drug delivery and manufacturing.

Contact details

171 Oyster Point Blvd., Suite 500
United States
+1 (415) 8652066

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$256.54 million
Shares in issue:
41.31 million
United States
US dollar

Key personnel

  • Faraz Ali
    Chief Executive Officer, Director
  • Leone Patterson
    Chief Financial and Business Officer
  • Timothy Hoey
    Chief Scientific Officer
  • Whittemore Tingley
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.